FTAI FTAI Aviation Ltd.
FTAI Aviation Ltd. owns, acquires, and sells aviation equipment for the transportation of goods and people worldwide. It operates in two segments, Aviation Leasing and Aerospace Products. The Aviation Leasing segment owns, leases, manages, and sells aircraft and aircraft engines. As of December 31, 2025, this segment owned and managed 290 aviation assets consisting of 47 commercial aircraft and 243 engines, including eight aircraft and seventeen engines in Russia. The Aerospace Products segment develops, manufactures, repairs/refurbishes, and sells aircraft engines and aftermarket components for the commercial aircraft engines. It also engages in the offshore energy business, which consists of vessels and equipment that support offshore oil and gas activities and production. FTAI Aviation Ltd. has a strategic collaboration with Aeronautical Engineers, Inc. The company was founded in 2011 and is headquartered in New York, New York.…
Industry Peers
Aerospace & DefenseKey Statistics
About FTAI Aviation (NASDAQ: FTAI)
›
FTAI Aviation (NASDAQ: FTAI) is listed on Nasdaq, where its shares trade in USD. It belongs to the Aerospace & Defense industry, part of the Industrials sector, and reports about 985 employees.
The shares were at 180.20 USD on 13 November 2026, up 18.0% over 52 weeks. Its 52-week range is 146.48 USD to 323.51 USD: the price is 44.3% below the high and 23.0% above the low.
At a market capitalisation of 18.43B USD, it trades at 36.6 times trailing earnings and 14.4 times forward earnings. The median trailing P/E of its 19 largest Aerospace & Defense peers is 31.7, a premium of 15% for FTAI. It pays a dividend yielding 1.09% (it pays out 34% of its earnings), against a median of 1.49% among the dividend payers in that peer group.
FTAI Aviation reports return on equity of 149.9%, an operating margin of 23.4% and revenue up 46.6% year over year.
Its debt exceeds its cash by 3.11B USD, a debt-to-equity ratio of 10.32. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 11 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 341.82 USD is 89.7% above the current price. The next earnings report is expected on 24 February 2027.